Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
about
A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinomaCurcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsSaponin 1 induces apoptosis and suppresses NF-κB-mediated survival signaling in glioblastoma multiforme (GBM).Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response.Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers.Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.Future directions and treatment strategies for head and neck squamous cell carcinomasPhase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoCan medical herbs stimulate regeneration or neuroprotection and treat neuropathic pain in chemotherapy-induced peripheral neuropathy?A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinomaMolecular targeted therapies in head and neck cancer--an update of recent developments-Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?Pharmacotherapy for squamous-cell carcinoma of the head and neck.Development of targeted therapy for squamous cell carcinomas of the head and neck.Novel targeted therapies in head and neck cancer.Using NF-κB as a molecular target for theranostics in radiation oncology research.Targeted therapy in head and neck cancer.Autophagic action of new targeting agents in head and neck oncology.Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis.Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing AutophagyInvestigational drugs for head and neck cancer.Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.Preserving biological heterogeneity with a permuted surrogate variable analysis for genomics batch correction.Virus reactivation: a panoramic view in human infectionsEpithelial plasticity and cancer stem cells: Major mechanisms of cancer pathogenesis and therapy resistanceApplication of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma.
P2860
Q27853046-D681E23C-BE93-45F5-B278-8BA02702C4E0Q34163076-B97B50C9-615A-4E11-B04A-297C56D58C3CQ34218976-05DB36E5-8A2B-4BAB-9B7E-24473458224DQ35053956-29F5378C-4885-4711-9F1D-167136A61F28Q35223807-CAAFCC08-FECE-4306-BBB5-1B669C29F2A1Q35741628-DB3E1399-102D-4D3C-AD22-3DF532B7D6DCQ35790990-A7BBA858-99DA-4C49-93E8-E8C8D2BBB8CBQ36012652-87F5BDCE-D051-4260-9FB7-C13498A3F8DFQ36177257-CE1CB9A8-E49E-4461-8EAB-F3A3F51FF425Q36947423-0067725F-0AD0-434B-A665-8AECF9E908E1Q37105226-740E45E7-6730-449F-A1F6-E79CCE7C2EE1Q37248229-0ECEFA9B-DB09-4D0F-8863-7C3989A96151Q37732457-1FE25479-6685-4D39-92D8-23E0E90F0957Q37799220-323E0AD3-2D1E-468D-A7BE-23CB8C9B9CB0Q37831351-5855F780-2D72-4499-BF80-D1076C950543Q37854706-B3F3F2DF-BC45-4B41-B043-F5207E0D4BB1Q37975224-8DA85FA5-D3A3-4E72-B5B8-20472BE29AC4Q37988573-6331672D-B3B9-4684-AAA4-CC58888A9613Q37988981-D87742D7-CB0E-4DAA-AC82-D52DD60394A9Q38028794-BB20FCB3-FAF7-4A44-B935-8E2B23CC8215Q38238365-BF8B30AA-99B1-4385-878F-2A7493F58667Q38258843-00EDCB21-B293-4DF5-822F-D1A7815D4569Q38701979-F3D065CB-497B-47E3-A7B7-D5FCE3649DB8Q38760399-95D4CB1B-973D-457C-B253-943C54FA95BFQ38800788-5FF9CAD4-B827-4497-A6BD-AF045B65FC7DQ38986185-18F190D2-8466-4EFB-A3DA-66459E12FACEQ39179186-78827AE7-AC19-4214-A051-AC45E1EE8147Q39723484-A012E308-24EC-4B66-A92D-FFCC830746E5Q41608178-2267C1E4-EF83-4392-9168-99276E30289EQ54979771-F3A0381D-D2C2-40FC-806A-0E3524F0BB26
P2860
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Nuclear factor-kappa B pathway ...... d neck squamous cell carcinoma
@ast
Nuclear factor-kappa B pathway ...... d neck squamous cell carcinoma
@en
type
label
Nuclear factor-kappa B pathway ...... d neck squamous cell carcinoma
@ast
Nuclear factor-kappa B pathway ...... d neck squamous cell carcinoma
@en
prefLabel
Nuclear factor-kappa B pathway ...... d neck squamous cell carcinoma
@ast
Nuclear factor-kappa B pathway ...... d neck squamous cell carcinoma
@en
P2093
P2860
P356
P1433
P1476
Nuclear factor-kappa B pathway ...... d neck squamous cell carcinoma
@en
P2093
A J Cmelak
B A Murphy
H Hatakeyama
J Netterville
P2860
P304
P356
10.1093/ANNONC/MDP390
P577
2009-10-22T00:00:00Z